AcelRx Gains on Dsuvia Study Results

(MENAFN - Baystreet.ca) AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) rose Monday on the results of research into its pain medication.
The Redwood City, Calif.-based AcelRx Pharmaceuticals, earlier during the month, announced an investigator-initiated study to assess the perioperative use of Dsuvia (sufentanil sublingual tablet) for same-day surgical procedures in patients on buprenorphine therapy for opioid-use disorder or chronic pain management.
The principal investigator, Dr. Naum Shaparin, is the Interim Chair of the Department of Anesthesiology and Director of the Multidisciplinary Pain Program at Montefiore Medical Center and Professor of Anesthesiology at Albert Einstein College of Medicine. The study was to evaluate the efficacy and safety of Dsuvia for perioperative management of surgical pain in patients on buprenorphine treatment.

Related Keywords

Naum Shaparin , Acelrx Pharmaceuticals , Acelrx Pharmaceuticals Inc , Multidisciplinary Pain Program At Montefiore Medical Center , Department Of Anesthesiology , Nasdaq , Redwood City , Interim Chair , Multidisciplinary Pain Program , Montefiore Medical Center , Albert Einstein College , துறை ஆஃப் மயக்கவியல் , நாஸ்டாக் , ரெட்வுட் நகரம் , இடைக்கால நாற்காலி , மான்டிஃபியோர் மருத்துவ மையம் , ஆல்பர்ட் ஐன்ஸ்டீன் கல்லூரி ,